Population enrichment strategy using APOE ε4 genotype in tau‐targeting trials for preclinical Alzheimer's disease

Abstract

Background: Trials in preclinical Alzheimer's disease (AD) are becoming increasingly important, as AD pathological changes appear decades before dementia onset. Amyloid‐beta (Aβ) pathology and the apolipoprotein E ε4 ( APOE ε4) carriership jointly accelerate tau tangle accumulation.